ENTOD Pharmaceuticals has introduced COLLADERM, an advanced transdermal collagen gel serum, at the 54th National Conference of the Indian Association of Dermatologists, Venereologists and Leprologists (DERMACON 2026). The product is now commercially available and positioned as a dermatologist-led, prescription-focused regenerative skincare solution in the Indian market. (Express Pharma)
Technology Transfer and India-Specific Optimization
COLLADERM was originally developed in the United Kingdom using AI-driven bio-engineering platforms and has been exclusively licensed to ENTOD Pharmaceuticals for distribution and manufacture in India. Formulation optimisation was undertaken at ENTOD’s DSIR-approved R&D centre in India, with specific adjustments for Indian skin biology and climatic conditions to support deeper skin renewal and hydration performance in localized usage contexts. (Express Pharma)
The serum incorporates the Quattro Collagen System, combining Type III and Type XVII recombinant vegan collagens of varying molecular weights, designed to enhance structural skin support. This collagen matrix is paired with a transdermal liposomal delivery technology termed TRANSCELLAR, intended to facilitate enhanced penetration and cellular uptake relative to conventional topical collagen formats. Supporting excipients include hyaluronic acid, glycerin and vitamin C to improve hydration and bioavailability of active ingredients. (Express Pharma)
Scientific Positioning and Clinical Context
Collagen remains a central target for formulations addressing hydration, elasticity and visible firmness. Traditional modalities such as oral collagen supplements or injectable collagen formulations face limitations in bioavailability and procedural complexity, respectively. In contrast, bio-engineered collagens integrated with transdermal delivery science may offer deeper structural support and functional benefits in clinical skincare settings. (The New Indian Express)
ENTOD’s CEO, Nikkhil K. Masurkar, highlighted that COLLADERM reflects a translational approach to skincare innovation, combining advanced molecular design with dermatologist-anchored clinical relevance. Expert clinicians who reviewed the product emphasise its potential to address limitations in penetration and performance seen with conventional topical collagen systems. (The New Indian Express)
Regulatory, Commercial and Manufacturing Implications
From a regulatory perspective, products positioned as dermatologist-led regenerative therapies may require careful classification under India’s cosmetic and medicinal product frameworks. Although COLLADERM is marketed as a skincare serum, its structural regeneration claims and transdermal delivery system raise considerations for technically aligning claim substantiation with permissible regulatory boundaries under the Drugs and Cosmetics Act, 1940 and associated rules where applicable.
The technology transfer to local manufacture under the Make in India initiative supports supply chain localisation and quality oversight. For contract manufacturers and formulation partners, this underscores the operational value of integrating advanced delivery platforms with scalable production processes compliant with local and international GMP standards. (The New Indian Express)
Strategic Outlook
COLLADERM’s launch illustrates several broader industry trends:
- Utilisation of generative AI tools in bio-active design and formulation optimisation
- Integration of advanced delivery technologies to improve transdermal performance
- Strategic localisation of globally developed R&D platforms within India
- Increasing prominence of dermatologist-led product positioning in premium skincare segments
For OEM and private-label partners, advanced transdermal systems represent a frontier in clinical skincare.